Industry Background:
Humira (Adalimumab), is an anti-TNF drug used for the treatment of ulcerative colitis, rheumatoid arthritis, Crohn’s disease psoriatic arthritis, etc. When a TNF alpha binds to TBF alpha receptors in an inflammatory response to autoimmune disease, lowers the chances of inflammatory response. Further, increasing prevalence of diseases like arthritis, psoriasis diseases and high investment in R & D of patent drugs and biosimilars are anticipated to propel the market growth.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
Key Companies Profiled | AbbVie Inc.(United States), Eisai Co., Ltd. (Japan), Cadila Pharmaceuticals (India), Torrent Pharmaceuticals Ltd. (India), Amgen Inc. (United States) and Boehringer Ingelheim International GmbH (Germany) |
According to AMA, the market for Humira is expected to register a CAGR of 25.0% during the forecast period to 2030. This growth is primarily driven by Increasing Prevalence of Chronic Diseases such as Crohn's Disease and Sedentary Lifestyle of Consumers Leading to Growth in Medical Conditions like Arthritis.
Globally, a noticeable market trend is evident Well Structured Regulatory Framework by the Government for the Humira Drug
The Health Care Supplies sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as AbbVie Inc.(United States), Eisai Co., Ltd. (Japan), Cadila Pharmaceuticals (India), Torrent Pharmaceuticals Ltd. (India), Amgen Inc. (United States) and Boehringer Ingelheim International GmbH (Germany), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The global Humira market is consolidated with very few players trying to compete with one another on the basis of price. Most of the leading players are focused on the development of Humira biosimilars for the treatment.
Key Developments in the Market:
June 2018, AbbVie GK and Eisai Co., Ltd. announced that HUMIRA for Subcutaneous Injection 20 mg Syringe 0.2 mL, a new pediatric formulation of HUMIRA (generic name: adalimumab [recombinant], “HUMIRA”), a fully human anti-TNF- monoclonal antibody formulation, was launched after being listed in the National Health Insurance reimbursement price list on June 15, 2018 .
In September 2017, AbbVie GK company won a patent litigation battle with Amgen. Drugmakers AbbVie Inc. and Amgen Inc. reached a patent-dispute settlement requiring Amgen to wait until 2023 to start selling a lower-priced copy of the world’s top-selling drug, AbbVie’s arthritis treatment Humira, in the United States.
Influencing Trend:
Well Structured Regulatory Framework by the Government for the Humira Drug and Increasing Number of Product Pipeline of Humira Drug
Market Growth Drivers:
Increasing Prevalence of Chronic Diseases such as Crohn's Disease and Sedentary Lifestyle of Consumers Leading to Growth in Medical Conditions like Arthritis
Challenges:
Side Effects associated with the Humira Drugs among Some Patients
Restraints:
High Cost Factor of Humiria Drug is hampering the Market Growth
Opportunities:
Focus of Market Players on the Development of Humira Biosimilars for the Treatment of Rheumatoid arthritis and Psoriasis and Increasing Investment in Healthcare Infrastructure
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Humira Market
- Analysis about New Entrants in Humira Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators
Against this Challenging Backdrop, Humira Study Sheds Light on
The Humira Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Humira industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Humira industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.